医学
骨质疏松症
药品
多发性骨髓瘤
骨溶解
双膦酸盐
癌症
骨病
不利影响
临床试验
药理学
内科学
外科
作者
Lianping Xing,Frank H. Ebetino,Robert K. Boeckman,Venkat Srinivasan,Jianguo Tao,Tomi K. Sawyer,Jinbo Li,Zhenqiang Yao,Brendan F. Boyce
出处
期刊:Bone
[Elsevier BV]
日期:2020-06-23
卷期号:138: 115492-115492
被引量:48
标识
DOI:10.1016/j.bone.2020.115492
摘要
The skeleton is affected by numerous primary and metastatic solid and hematopoietic malignant tumors, which can cause localized sites of osteolysis or osteosclerosis that can weaken bones and increase the risk of fractures in affected patients. Chemotherapeutic drugs can eliminate some tumors in bones or reduce their volume and skeletal-related events, but adverse effects on non-target organs can significantly limit the amount of drug that can be administered to patients. In these circumstances, it may be impossible to deliver therapeutic drug concentrations to tumor sites in bones. One attractive mechanism to approach this challenge is to conjugate drugs to bisphosphonates, which can target them to bone where they can be released at diseased sites. Multiple attempts have been made to do this since the 1990s with limited degrees of success. Here, we review the results of pre-clinical and clinical studies made to target FDA-approved drugs and other antineoplastic small molecules to bone to treat diseases affecting the skeleton, including osteoporosis, metastatic bone disease, multiple myeloma and osteosarcoma. Results to date are encouraging and indicate that drug efficacy can be increased and side effects reduced using these approaches. Despite these successes, challenges remain: no drugs have gone beyond small phase 2 clinical trials, and major pharmaceutical companies have shown little interest in the approach to repurpose any of their drugs or to embrace the technology. Nevertheless, interest shown by smaller biotechnology companies in the technology suggests that bone-targeting of drugs with bisphosphonates has a viable future.
科研通智能强力驱动
Strongly Powered by AbleSci AI